Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lifestyle-Induced Redox-Sensitive Alterations: Cross-Talk among the RAAS, Antioxidant/Inflammatory Status, and Hypertension.
Szabó R, Börzsei D, Hoffmann A, Lesi ZN, Gesztelyi R, Juhász B, Szebeni GJ, Osman J, Sebestyén J, Nagy A, Szegedi S, Varga C, Pósa A. Szabó R, et al. Among authors: sebestyen j. Oxid Med Cell Longev. 2021 Oct 25;2021:3080863. doi: 10.1155/2021/3080863. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34733402 Free PMC article.
Multiple Applications of Different Exercise Modalities with Rodents.
Börzsei D, Szabó R, Hoffmann A, Harmath A, Sebestyén J, Osman J, Juhász B, Priksz D, Varga C, Pósa A. Börzsei D, et al. Among authors: sebestyen j. Oxid Med Cell Longev. 2021 Nov 25;2021:3898710. doi: 10.1155/2021/3898710. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34868454 Free PMC article. Review.
Resveratrol as a Promising Polyphenol in Age-Associated Cardiac Alterations.
Börzsei D, Sebestyén J, Szabó R, Lesi ZN, Pálszabó A, Pálszabó P, Szász A, Priksz D, Juhász B, Veszelka M, Turcsán Z, Deim Z, Varga C, Pósa A. Börzsei D, et al. Among authors: sebestyen j. Oxid Med Cell Longev. 2022 Jun 18;2022:7911222. doi: 10.1155/2022/7911222. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35761875 Free PMC article.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Bisphosphonates use in children.
Sebestyen JF, Srivastava T, Alon US. Sebestyen JF, et al. Clin Pediatr (Phila). 2012 Nov;51(11):1011-24. doi: 10.1177/0009922812452118. Epub 2012 Aug 30. Clin Pediatr (Phila). 2012. PMID: 22935217 Review.
Advances in pediatric renal replacement therapy.
Sebestyen JF, Warady BA. Sebestyen JF, et al. Adv Chronic Kidney Dis. 2011 Sep;18(5):376-83. doi: 10.1053/j.ackd.2011.07.003. Adv Chronic Kidney Dis. 2011. PMID: 21896380 Review.
47 results